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ARTICLE

Induction of high-affinity IgE receptor
on lung dendritic cells during viral infection
leads to mucous cell metaplasia
Mitchell H. Grayson,1 Dorothy Cheung,1 Michelle M. Rohlfing,1
Robert Kitchens,1 Daniel E. Spiegel,1 Jennifer Tucker,2 John T. Battaile,2
Yael Alevy,2 Le Yan,2 Eugene Agapov,2 Edy Y. Kim,2
and Michael J. Holtzman2,3
of Allergy and Immunology, 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine,
and 3Department of Cell Biology, Washington University School of Medicine, Saint Louis, MO 63110

Respiratory viral infections are associated with an increased risk of asthma, but how acute
Th1 antiviral immune responses lead to chronic inflammatory Th2 disease remains undefined. We define a novel pathway that links transient viral infection to chronic lung disease
with dendritic cell (DC) expression of the high-affinity IgE receptor (FcRI␣). In a mouse
model of virus-induced chronic lung disease, in which Sendai virus triggered a switch to
persistent mucous cell metaplasia and airway hyperreactivity after clearance of replicating
virus, we found that FceRIaⴚ/ⴚ mice no longer developed mucous cell metaplasia. Viral
infection induced IgE-independent, type I IFN receptor–dependent expression of FcRI␣ on
mouse lung DCs. Cross-linking DC FcRI␣ resulted in the production of the T cell chemoattractant CCL28. FceRIaⴚ/ⴚ mice had decreased CCL28 and recruitment of IL-13–producing
CD4ⴙ T cells to the lung after viral infection. Transfer of wild-type DCs to FceRIaⴚ/ⴚ mice
restored these events, whereas blockade of CCL28 inhibited mucous cell metaplasia. Therefore, lung DC expression of FcRI␣ is part of the antiviral response that recruits CD4ⴙ T
cells and drives mucous cell metaplasia, thus linking antiviral responses to allergic/asthmatic Th2 responses.

CORRESPONDENCE
Mitchell H. Grayson:
wheeze@allergist.com
Abbreviations used: ATCC,
American Type Culture Collection; IFNAR, type I IFN receptor; PI, postinnoculation; SeV,
Sendai virus.

The risk of asthma from severe paramyxoviral
infection in both human and experimental
models is well documented (1–3). This virally
imparted risk presents an interesting paradox;
although the primary antiviral response is dominated by production of IFN/ and IL-12,
which are hallmarks of a Th1 response, rhinorrhea and mucous cell metaplasia also develop.
These conditions are driven by IL-13, which is
a hallmark Th2 cytokine (4, 5). The production of antiviral IgE, along with neutralizing
IgG antibodies, provides a further link between
these disparate responses (6–10). In fact, IgE serum concentrations have been correlated with
subsequent wheezing in infants with respiratory
viral infection and with the risk of otitis media
with effusion in children (10, 11). How a Th1biased response generates a Th2 phenotype is
not known, although we now show that the
high-affinity receptor for IgE on DCs bridges
The online version of this article contains supplemental material.
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the antiviral Th1 response to the atopic/proasthmatic Th2 response.
The role of the high-affinity receptor for
IgE (FcRI) on human conventional DCs (cDCs)
has been assumed to be antigen focusing, with
expression being tightly regulated by serum
IgE levels, much like it is on basophils (12, 13).
FcRI has not been reported on mouse DCs,
and little is known of what role it might play
during an antiviral response. Indeed, the role
of the cDCs in an antiviral immune response is
not fully understood. Initial lung cDC migration
to draining lymph nodes, and subsequent antigen presentation, has been examined (14–16).
However, the role of those cDCs that remain
in or are attracted to the lung parenchyma during a primary response has not been evaluated.
Although, in the case of secondary viral infections or challenge responses to OVA, the evidence suggests that these cells are involved in
recruitment of memory effector T cells (17, 18).
We have developed a mouse model of viral
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bronchiolitis that reproduces disease traits associated with
asthma (2). In this model, FcRI was expressed on lung cDCs
only during the antiviral response, and these cells were critical for the development of postviral mucous cell metaplasia.
Indeed, mice deficient in FcRI (FceRIa–/–) failed to recruit
IL-13–producing CD4 T cells to their lungs after viral infection. Cross-linking the -chain of FcRI (FcRI) on lung
cDCs produced a CD4 T cell chemoattractant, CCL28, and
blockade of this chemokine prevented development of postviral mucous cell metaplasia. Thus, these studies provide a
novel insight into how the antiviral response leads to a potent
Th2 response through FcRI on lung cDCs.

Paramyxoviral infection induces high-level expression
of FcRI␣ on resident lung DCs
We next identified which cell type in the lung might express
FcRI in the setting of viral infection. In rodents, the highaffinity IgE receptor has been identified only on mast cells,
basophils, and possibly eosinophils (19). However, in humans, this receptor is also found on skin and peripheral blood
cDCs, as well as plasmacytoid DCs (pDCs), albeit as a trimeric
form (FcRI) that lacks the FcRI chain (13, 20, 21).
Therefore, we questioned whether this form of the receptor
might also be found on lung parenchymal cDCs after viral
infection. Using forward/side scatter characteristics and a
high level of CD11c expression to identify lung cDCs, we
have observed that SeV infection leads to a rapid and sustained decrease in the number of lung cDCs, but the cDC
population remaining in the lung becomes more mature and
differentiated (22). Therefore, we examined this population
of resident cDCs in more detail.
Before infection, lung cDCs failed to express FcRI; however, by PI day 3, this population began to express the  chain
2760

Figure 1. Inhibition of chronic mucous cell metaplasia after viral
infection in FceRIaⴚ/ⴚ mice. (A) FceRIa/ and WT littermate control
mice were inoculated with SeV, and lung sections were immunostained
for Muc5ac at PI day 0 and 21. Representative images from PI day 21 are
shown. Bar, 40 m. (B) Quantification of mucous cells based on immunostaining conditions from A. (C) Lungs from A were subjected to real-time
PCR for Muc5ac mRNA. For B and C, values represent the mean the
SEM for three to five mice. *, P 0.05 versus WT PI day 21.

of the high-affinity receptor for IgE (FcRI), and this expression remained detectable for 2–3 wk after SeV inoculation
(Fig. 2, A and B). This response was specific to lung cDCs because there was no detectable expression of FcRI on cDCs
isolated from draining lymph nodes or spleen during SeV infection (unpublished data). CD23, the low-affinity receptor
for IgE, was not induced during the infection (Fig. 2 B). Using intranasal administration of the intravital dye CFSE, which
labeled lung cells present at the time of its administration but
not cells that subsequently migrated into the lung, we were
able to show that FcRI-expressing cDCs were present in
the lung at the time of the initial viral inoculation and had not
migrated into the lung after the onset of infection (Fig. 2,
C and D). The level of expression of FcRI on lung cDCs
at PI day 7 was similar to levels seen on c-kit lung mast cells
(Fig. 2, A and E). Increased expression of FcRI after viral infection was relatively selective for cDCs and mast cells because
we did not detect expression of FcRI on lung CD4 or
CD8 T cells, B220 B cells, Mac-3 macrophages, or Gr-1
neutrophils (unpublished data). Expression of FcRI was detected on 20–40% of lung pDCs at PI day 3 (unpublished data),
FcRI AND VIRUS-INDUCED MUCOUS CELL METAPLASIA | Grayson et al.
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RESULTS
FceRIa–/– mice fail to develop airway mucous cell metaplasia
We infected FceRIa–/– mice or WT littermates with the
mouse paramyxovirus Sendai virus (SeV). Each strain exhibited similar morbidity (as monitored by weight loss),
development of an adaptive immune response (as indicated
by the development of SeV-specific CD8 T cells), and
clearance of virus from the lung (based on SeV copy number)
during the acute phase of viral infection (Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20070360/DC1).
Previous work in this model has shown that replicating
virus is fully cleared by postinoculation (PI) day 12, with the
subsequent development of long-lasting mucous cell metaplasia evident by PI day 21 (2). Despite a similar acute response to viral infection, we found a marked decrease in
the number of Muc5ac-expressing mucous (goblet) cells in
the airways of FceRIa–/– mice compared with WT mice at
PI day 21 (Fig. 1). We have previously shown that Muc5ac
induction by PI day 21 depends on production of IL-13 (5).
Therefore, these findings suggested a link between FcRI
expression and IL-13 production in the airway response to
viral infection.
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which is consistent with reports of FcRI on human
pDCs (21). This pDC population was distinct from the lung
cDC population because FcRI-expressing lung cDCs did
not express the pDC/B cell marker B220 (Fig. S2 A, available
at http://www.jem.org/cgi/content/full/jem.20070360/DC1).
Expression of FcRI did not influence cDC maturation or
differentiation during viral infection. We found no difference
in the levels of expression of MHC class II, CD11b, CD80, or
CD86 between lung cDCs from FceRIa–/– versus WT mice
(Fig. S2, A and B). Similarly, we found no influence of FcRI
on the expression of CD23.
Based on work with isolated cells, mice have been reported
to be obligate expressers of the tetrameric form (FcRI)
of FcRI (23). To determine if mouse lung cDCs were,
indeed, expressing the tetrameric and not trimeric form of
the receptor, we analyzed mouse lung cDCs for expression
of each FcRI component chain. Immunoprecipitation of
FcRI with an anti-FcRI antibody, and subsequent Western
blot with anti-FcRI or -FcRI antibodies, showed that
lung cDCs isolated after SeV infection expressed FcRI,
but not FcRI (Fig. 2 F). In contrast, MC9 mast cells expressed
both FcRI and FcRI. In concert with these findings for
JEM VOL. 204, October 29, 2007

FcRI proteins, real-time PCR assays showed that lung cDCs
expressed FcRI␣, but not FcRI␤ mRNA after viral infection, whereas MC9 mast cells contained high levels of both
FcRI␣ and FcRI␤ mRNA (Fig. S2 C). Thus, mouse lung
cDCs express the trimeric (FcRI) form of the FcRI
receptor. This is the same form of FcRI that is expressed by
human DCs, but expression on mouse cDCs requires induction by a productive viral infection. This requirement may
explain the failure to detect FcRI expression on mouse DCs
in previous works.
Type I IFN receptor, but not IgE, regulates DC expression
of FcRI␣
Next, we explored what component of the antiviral response
is responsible for induction of FcRI expression on lung
cDCs during a paramyxoviral infection. Serum IgE level
tightly regulates expression of the high-affinity IgE receptor in
humans, so we reasoned that total IgE and, more likely, SeVspecific IgE might drive FcRI receptor expression after viral
infection in mice. However, we found that serum total IgE
and SeV-specific IgE do not increase until PI day 7 (Fig. 3 A).
This time course lags behind the onset of expression of FcRI
2761
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Figure 2. Up-regulation of FcRI expression on lung DCs after viral infection. (A) WT mice were inoculated with SeV, and CD11c lung cDCs or
c-kit mast cells (MC) were analyzed by flow cytometry using anti-FcRI mAb and isotype control mAb at PI day 0 and 7. (B) Conditions in A were used
for flow cytometry for FcRI and CD23 on the indicated PI day. Values represent the mean the SEM for n 6 mice. *, P 0.05 versus PI day 0. (C) WT
mice were given PBS ([–] CFSE) or CFSE ([+] CFSE) intranasally and inoculated with SeV. Lung cDCs were isolated at PI day 7, and expression of CFSE
and FcRI was determined by flow cytometry. (D) Quantification of data from C. Values represent the mean the SEM for n 3 mice. (E) Lung cDCs
(CD11c) and mast cells (c-kit) were analyzed by flow cytometry for FcR1, as in A. Values represent the mean the SEM for fold mean fluorescence
intensity FcRI signal versus isotype control mAb for three mice per time point. (F) Cell lysates from lung cDCs (PI day 5) or MC/9 mast cells were subjected to immunoprecipitation with anti-FcRI mAb. Immunoprecipitated complexes (IP) were then Western blotted with anti-FcRI or -FcRI mAb.
Representative blots are shown for two separate experiments.
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Figure 3. Effect of IgE levels and IFN signaling on up-regulation
of FcRI on lung cDCs after viral infection. (A) WT mice were
inoculated with SeV, and serum was analyzed for total and SeV-specific
IgE levels. Values represent the mean the SEM for three to six mice.
(B) IgE/ and WT control mice were inoculated with SeV, and lung
cDCs were analyzed by flow cytometry using anti-FcRI and isotype
control mAbs. (C) IFNAR/ and WT mice were inoculated with SeV, and
lung cDCs were analyzed at PI day 5, as in B. For conditions in C, quantification of fold increase in mean fluorescence intensity for FcRI
over isotype control (D) and percentage of lung cDCs expressing FcRI
(E). Values represent the mean the SEM for four to eight mice
per group.

on lung cDCs, suggesting that the level of IgE is not driving
the expression of FcRI receptor under these conditions. In
fact, we found that IgE-deficient (IgE/) mice continued to
develop the same increase in FcRI expression on lung
cDCs as their WT littermates after viral inoculation (Fig. 3 B).
2762

Lung cDCs from virus-infected mice drive IL-13 production
from CD4ⴙ T cells
Because IL-13 is thought to drive postviral mucous cell metaplasia, and Th2 cells are thought to be a likely source of IL-13,
we reasoned that generation of Th2 cells might be altered as
a result of FcRI engagement on cDCs (5). CD8 cDCs,
like those found in the lung, have been shown to drive T cell
development toward a Th2 phenotype in vitro (24). Therefore, to determine if induction of IL-13–producing CD4
T cells depended on engagement of FcRI, we examined
IL-13 production in an in vitro cell culture system that contains
CD4 T cells and cDCs. OVA-specific CD4 T cells (OT-II
cells) were cultured with lung cDCs isolated from WT or
FceRIa/ mice with or without SeV infection. We isolated
cDCs at PI day 7 and verified that these cDCs had not yet
bound IgE at this time point (unpublished data). We found
that OT-II CD4 T cells produced IL-13 when cultured
with antigen and cDCs, regardless of whether cDCs were
FcRI AND VIRUS-INDUCED MUCOUS CELL METAPLASIA | Grayson et al.
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Therefore, IgE levels do not appear to regulate the appearance
of FcRI on lung cDCs after viral infection in mice.
Given that initial expression of FcRI developed at the
same time as IFN-dependent responses in this viral model, we
examined whether IFN signaling was necessary for FcRI expression. Indeed, we found that type I IFN receptor (IFNAR)–
deficient (IFNAR/) mice no longer exhibited an increase
in FcRI expression on lung cDCs during viral infection
(Fig. 3, C–E). In contrast, mice that were deficient for CD1d,
CD4, CD8, perforin, or MyD88 gene expression showed no
defect in FcRI expression after viral infection (unpublished data). Thus, although IFNAR is critical for expression
of FcRI on lung cDCs after viral infection, there is no
substantial role for NKT cells, CD4 T cells, or CD8 T cells,
or for the innate antiviral perforin- or MyD88-dependent Tolllike receptor pathways in this process.
We next examined the mechanism for IFN-dependent
expression of FcRI on DCs. We recognized that direct IFN
treatment of human lung pDCs failed to increase FcRI
expression (21). This finding suggested that IFN-dependent
increases in FcRI expression on lung DCs may involve
other cell types besides DCs. Accordingly, we next determined
whether IFNAR expression on cDCs was necessary for
FcRI expression after viral infection. For these experiments,
we purified lung cDCs from IFNAR/ and WT control
mice. We verified that the cells we purified exhibited typical
DC morphology (Fig. 4). Purified lung cDCs were loaded
with CFSE (to discriminate from endogenous cDCs) and
transferred into WT or IFNAR/ recipients. We found that
either IFNAR/ or WT cDC transfer into WT mice allowed
for expression of FcRI on cDCs (Fig. S3, available at
http://www.jem.org/cgi/content/full/jem.20070360/DC1).
In contrast, transfer of either genotype of cDCs into IFNAR/
mice did not permit expression of FcRI on cDCs after
viral infection. These findings imply that IFN acts through
another intermediate cell to activate FcRI expression on
lung cDCs.
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isolated from WT or FceRIa/ mice or from infected or uninfected mice (Fig. 5 A). Furthermore, cross-linking FcRI
had no effect on T cell production of IL-13 or proliferation
(Fig. 5 A and not depicted). Thus, we conclude that lung
cDCs are capable of driving the development of IL-13–producing CD4+ Th2 cells, but this process does not require cDC
expression or activation of FcRI.
Cross-linking FcRI␣ on lung DCs produces the T cell
chemoattractant CCL28
Because we did not detect a requirement for cross-linking
FcRI in the development of the T cell cytokine response,
we next assessed whether FcRI might be involved in the induction of T cell chemoattractants. Lung cDCs were purified
from WT mice by immunomagnetic selection at PI day 5. The
purified cells were then cultured for 18 h with a cross-linking
antibody against FcRI or a control hamster IgG. Supernatants from these cultures were then used in a modified Boyden
chamber assay to assess whether a functional T cell chemoattractant had been produced. Supernatants from FcRI crosslinked cDCs induced significantly more CD4 T cell migration
than did IgG control supernatants, indicating that engagement
of the receptor led to production of a CD4 T cell chemoattractant (Fig. 5 B). To identify the chemokine receptor for this
T cell chemoattractant, we added various chemokines (CCL5,
CCL22, and CCL27) to the upper chamber and evaluated the
effect on chemotaxis (Fig. S4 A, available at http://www.jem
.org/cgi/content/full/jem.20070360/DC1). Only CCL27
(C-TACK) inhibited T cell migration, indicating that the CD4
T cells were moving in response to a CCR10 agonist. Only
two known CCR10 agonists, CCL27 and CCL28 (MEC),
have been identified. Using blocking mAbs, we found that the
chemotactic activity was entirely caused by CCL28 (Fig. 5 B).
Of relevance to this work, CCL28 has been associated with
both human asthma and mouse models of asthma (25–27).
JEM VOL. 204, October 29, 2007

To establish that CCL28 expression was inducible in
cDCs with a more physiological stimulus of FcRI activation, we loaded lung cDCs from PI day 7 with IgE against
OVA. In this setting, we found that addition of OVA (by
cross-linking anti-OVA IgE bound to FcRI on the cDC)
caused a marked increase in CCL28 mRNA (Fig. 5 C). Similar results were obtained when using the anti-FcRI antibody to directly cross-link the receptor (unpublished data).
To determine whether FcRI activation also caused CCL28
expression in vivo, we returned to experiments with the mouse
model of virus-induced lung disease. Again, we found that
lung levels of CCL28 mRNA were increased after SeV infection in WT mice, and that this effect was lost in FceRIa/ mice
(Fig. 5 D). If CCL28 was being released with engagement of
FcRI, then we would expect differences in the frequency of
CD4 T cells in the lungs of FceRIa/ and WT mice after
viral infection. Indeed, we found that CD4 T cells were
significantly decreased in the lungs of FceRIa/ mice compared
with WT mice at PI day 21 (Fig. 5 E).
Because we have previously shown that mucous cell
metaplasia after viral infection is dependent on IL-13 production, we next examined the amount of IL-13 and GATA-3
(a Th2-specific transcription factor) message in lung CD4 T
cells of WT and FceRIa/ mice after SeV infection (5). We
found a significant decrease in the levels of IL-13 and GATA-3
mRNA in CD4 T cells from the lungs of FceRIa/ compared with WT mice (Fig. 5, F and G). These findings further
supported the proposal that inhibition of mucous cell metaplasia in FceRIa/ mice was based on decreased accumulation of IL-13–producing CD4 Th2 cells caused by a lack of
production of CCL28 by the resident FcRI lung cDCs.
We also examined IL-13 and GATA-3 mRNA levels in the
CD4 T cells that had or had not migrated in response to
CCL28 in vitro. We found that there was much greater expression of both IL-13 and GATA-3 mRNA in T cells that
2763
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Figure 4. Morphology of purified lung cDCs versus macrophages. Lung cDCs were isolated by positive immunomagnetic selection with macrophages obtained by BAL. Both cell preparations were cytocentrifuged onto slides (left two columns) and cultured in chamber slides with or without
10 g/ml LPS for 24 h at 37°C (right two columns), and then imaged with modified Wright’s stain and photomicrography. For each condition, representative
photomicrographs from three separate experiments are shown. Bars, 10 m.
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Figure 5. CCL28 production after activation of FcRI on lung cDCs. (A) Lung cDCs from WT or FceRIa/ mice that were uninfected (PI day 0) or
SeV-infected (PI day 7) were treated with or without anti-FcRI mAb or control IgG. Cells were loaded with OVA peptide and cocultured with OVA-specific CD4 T cells (OT-II) for 4 d at 37°C, followed by ELISA of cell supernatants for IL-13. Values represent the mean the SEM for four to seven experiments done in triplicate. (B) Lung cDCs were purified from PI day 5 and treated with an anti-FcRI mAb or control IgG for 18 h at 37°C. Cell
supernatants were assayed for chemotactic activity for naive CD4 T cells with and without treatment with anti-CCL28 or -CCL27 mAb. Values represent
the mean the SEM for three to six experiments done in triplicate. *, P 0.05 versus IgG supernatant; **, P 0.05 versus anti-CCL27 and no antibody
treatment. (C) Lung cDCs purified at PI day 7 were loaded with anti-OVA IgE and cultured with (+) or without (–) 3 g/ml OVA protein for 18 h at 37°C.
Cellular RNA was subjected to real-time PCR for Ccl28 mRNA. Values are corrected for Gapdh mRNA level and represent the mean the SEM for three
experiments. *, P 0.05 versus no OVA protein. (D) FceRIa/ and WT mice were inoculated with SeV, and lung levels of Ccl28 mRNA were determined by
real-time PCR at the indicated times. Values represent the mean the SEM for three to five mice. (E) Lung frequencies of CD4 T cells were quantified by
flow cytometry in WT and FceRIa/ mice at the indicated times. Values represent the mean the SEM for three to nine mice. (F) Lung CD4 T cells were
purified by positive immunomagnetic selection at PI day 21 and analyzed for Il-13 by real-time PCR. (G) Using conditions in F, expression of GATA-3
mRNA was analyzed by real-time PCR. (H) Percentage of total lung cells in the lymphocyte gate expressing CCR10 and CD4 by flow cytometry at PI day 0
or 10 in WT and FceRIa/ mice. For F–H, values represent the mean the SEM for three mice. *, P 0.05 versus WT mice for D–H. (I) CCR10 CD4 T
cells and CCR10 CD4 T cells were purified by flow cytometry at PI day 10 and subjected to real-time PCR for GATA-3 and T-bet. Values represent the
mean the SEM for the ratio of GATA-3 to T-bet from three experiments with three mice per experiment. *, P 0.05 versus CCR10 CD4 T cells.
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migrated compared with cells that did not migrate in response
to CCL28 (Fig. S4 B).
Because CCL28 binds to CCR10 to recruit immune
cells, we determined the level of CCR10 CD4 T cells in
the lungs of WT and FceRIa/ mice before and after viral
infection. We found an increase in CCR10 CD4 T cells
in WT mice after viral infection (Fig. 5 H). Furthermore, this
increase in CCR10 CD4 T cells did not develop in FceRIa/
mice. We also found that CCR10 CD4 lung T cells from
WT mice contained increased levels of GATA-3 mRNA
(typically found in Th2 cells) compared with T-bet mRNA
(typically found in Th1 cells; Fig. 5 I). Together, these findings provide further support for the proposal that activation
of FcRI on cDCs leads to preferential accumulation of
Th2 cells in the lung after SeV infection.

Blockade of CCL28 inhibits postviral mucous cell metaplasia
We next determined the role of CCL28 in the cascade leading to mucous cell metaplasia after viral infection. For these
experiments, we treated WT mice with an anti-CCL28–
blocking mAb or control IgG2b and monitored the development of mucous cell metaplasia at PI day 21. We found a
significant decrease in mucous cell metaplasia after treatment
with anti-CCL28 mAb compared with control IgG (Fig. 7,
A and B, and Fig. S6, available at http://www.jem.org/cgi/
content/full/jem.20070360/DC1). We observed no significant difference in the frequency of CD4 T cells in the lungs
of mice treated with either anti-CCL28 mAb or control
IgG2b (Fig. 7 C). This finding suggests that CCL28 is a chemotactic factor for immune cells producing IL-13 and driving mucous cell metaplasia after viral infection, but additional
chemoattractants also contribute to CD4 T cell accumulation in the lung in this setting.
JEM VOL. 204, October 29, 2007

Figure 6. Restoration of postviral mucous cell metaplasia in FceRIaⴚ/ⴚ
mice after lung cDC transfer. (A) Lung cDCs were isolated from WT or
FceRIa/ mice and transferred into FceRIa/ recipients 1 d before
inoculation with SeV. At PI day 21, lung sections were obtained for immunostaining for Muc5ac. Representative photomicrographs are shown. Bar,
40 m. (B) Quantification of immunostaining in A. Values represent the
mean the SEM for two to four recipient mice per group from two separate experiments; *, P 0.05 versus WT DCs transferred into FceRIa/
recipients. (C) For conditions in A, lung CD4 T cells were purified at PI
day 21 and analyzed for Il-13, GATA-3, and Gapdh mRNA by real-time
Q-PCR. Values represent the mean the SEM from two separate experiments with two to four recipient mice per experiment. *, P 0.05 versus
FceRIa/ cDCs transferred into FceRIa/ recipients.

DISCUSSION
In this study, we show that respiratory viral infection can
lead to expression and activation of FcRI on lung cDCs
and thereby drive the development of mucous cell metaplasia
even after the inciting infection is cleared. We examined lung
cDCs because we previously found that the migration and
maturation of this cell population was tightly regulated during respiratory viral infection (22). Indeed, the potent effects
of viral infection on DCs might explain why we have detected
FcRI on DCs in the mouse, whereas others have not previously found this receptor on DCs (28).
We have also shown that expression of FcRI in the setting of a productive viral infection requires an active type I
IFN response. In fact, expression of FcRI on cDCs quickly
returns to low levels with resolution of the antiviral response,
2765
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cDC reconstitution restores CD4ⴙ T cell accumulation
and mucous cell metaplasia after viral infection
To prove that FcRI expression on cDCs was necessary
for recruitment of CD4 Th2 cells to the lung and mucous
cell metaplasia after viral infection, we performed adoptive cell
transfer experiments with cDCs from WT or FceRIa/ mice
transferred into FceRIa/ recipients, followed by SeV inoculation. We found that reconstitution with WT cDCs restored
postviral mucous cell metaplasia in FceRIa/ recipient mice
(Fig. 6, A and B, and Fig. S5 A, available at http://www.jem
.org/cgi/content/full/jem.20070360/DC1). In contrast, transfer of FceRIa/ cDCs were unable to restore the development
of mucous cell metaplasia after viral infection. Furthermore,
we found that CD4 T cells isolated at PI day 21 from lungs of
FceRIa/ mice that had received WT cDCs expressed IL-13
and GATA-3 at significantly higher levels than mice that received cDCs from FceRIa/ mice (Fig. 6 C). We found no
difference in the engraftment of WT versus FceRIa/ cDCs,
with both genotypes of cDCs persisting for at least 6 d after
transfer to the recipient mice (Fig. S5 B). Together, these results indicate that FcRI on lung cDCs is critical for Th2 cell
recruitment and mucous cell metaplasia after viral infection.
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such that expression is nearly undetectable by 21 d after viral
inoculation. Previous work has shown that IgE levels regulate FcRI expression on mast cells. In addition, the low levels of FcRI expression found on mast cells from IgE/ mice
were attributed to IL-4 production (29). These findings now
indicate that FcRI expression on cDCs is also regulated by
type I IFN. Moreover, expression on cDCs can be regulated
independent of IgE levels because FcRI levels return to
baseline despite a persistent increase in IgE levels after viral
infection. Thus, FcRI on cDCs may be selectively regulated
by type I IFN, at least in the mouse. Human cDCs express
FcRI at baseline, but whether these levels are increased by
viral infection still needs to be determined (12, 13).
In that regard, the consequences of IgE production and
IgE–FcRI interaction in the setting of viral infection were
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Figure 7. Effect of CCL28 blockade on mucous cell metaplasia
after viral infection. (A) WT mice were inoculated with SeV and treated
with anti-CCL28 mAb or control IgG2b mAb every other day starting on PI
day 3. At PI day 21, lung sections were subjected to immunostaining for
Muc5ac, and representative photomicrographs are shown. Bar, 40 m.
(B) Quantification of immunostaining in A. (C) For conditions in A, the
frequency of lung CD4 T cells was monitored by flow cytometry. Values
represent the mean the SEM for four mice per group. *, P 0.05 versus
control IgG2b treatment.

also uncertain. Any possible pathogenic role for IgE-dependent signals remained undefined, despite recognition that viral
infections stimulate potent IgE responses along with neutralizing IgG antibodies (6–10). Furthermore, increased antiviral
IgE production is closely associated with subsequent wheezing in infants after respiratory viral infection (10). Moreover,
the two major pathogens linked to asthma pathogenesis, i.e.,
respiratory syncytial virus (a paramyxovirus-like SeV) and
rhinovirus, are both known to potently induce the production of IgE in humans (10, 30–33). Our findings provide
for a novel IgE-dependent mechanism in which an antiviral
response characterized by IFN production drives expression
of FcRI on lung cDCs. IgE engagement of the receptor
leads to release of soluble mediators that generate an atopic
response characterized by Th2 cell activation and IL-13 production. Consistent with this mechanism, others showed that
passive transfer of antiviral IgE can increase the airway hyperreactivity caused by respiratory syncytial virus infection in
mice, and that FcRI was necessary for this IgE-dependent
response (34). This effect was assumed to be caused by mast
cell activation during the viral infection. However, given the
very low dissociation kinetics of FcRI-bound IgE (Kd of
ⵑ109–1010 M), it is not clear that IgE during a primary viral infection would bind to mast cell FcRI in any significant
quantity during the acute infection (35). It is possible that the
rapid expression of FcRI on lung cDCs would make these
cells a better target cell for binding antiviral IgE because this
cell population would have a significant number of unoccupied receptors. Although we did not study this issue directly,
it is quite possible that virus-induced airway hyperreactivity, like
mucous cell metaplasia, is a result of engagement of FcRI on
lung cDCs and not mast cells or basophils.
The actions of FcRI found on mouse lung cDCs are
distinct from the previously described role of FcRI signaling on human DCs. In the human cells, FcRI is thought to
help target antigens to DCs (12). Because IgE production lags
behind expression of FcRI, it appears that IgE may act as a
signaling molecule for lung cDCs. Once an effective adaptive
immune response has been generated, virus-specific IgE will
be produced, bind to the cDCs, and be cross-linked by viral
antigen. This signals cDCs to produce CCL28 and recruit
effector Th2 cells. Because Th2 recruitment to the lung is antigen nonspecific, it is possible that this mechanism contributes
in other ways to allow the innate immune system to influence
the antiviral response (36). For example, regulatory T cells express CCR10 and may be another important target of CCL28
(37). Thus, FcRI engagement on lung cDCs may provide
mechanisms to down-regulate an ongoing Th1 response in
the lung after viral infection.
These results may also bear on the increased incidence of
asthma and allergic diseases that are being observed in more
industrialized countries. This observation has led to the “hygiene hypothesis,” in which cleaner living conditions and
decreased childhood bacterial infections are thought to drive
an increase in allergic disease (38). Our results suggest an additional mechanism that may explain the increased incidence
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Mouse generation and handling. C57BL/6; BALB/c; B6.129S2CD4+tm1Mak/J (CD4-null); B6.129S2-Cd8atm1Mak/J (CD8-null); and C57BL/6Prf1tm1Sdz/J (perforin-null) mice were obtained from The Jackson Laboratory.
TgN(OT-II.2a)Rag1tm1 (OT-II) mice on a C57BL6 background were obtained
from the Taconic NIAID Emerging Models Program (Germantown, NY).
C57BL6 mice deficient in CD1d were obtained from A. Bendelac (University of Chicago, Chicago, IL); IFNAR-null mice on a C57BL6 background
were obtained from J. Sprent (The Scripps Research Institute, La Jolla, CA);
MyD88-deficient mice and WT littermates on a mixed B6/129 background were a gift from M. Colonna (Washington University, St. Louis,
MO); FcRI-deficient mice on a C57BL6 background were obtained
from J.-P. Kinet (Harvard Medical School, Boston, MA); and IgE-deficient
mice on a BALB/c background were obtained from H. Oettgen (Harvard
Medical School, Boston, MA). Mice 6–20 wk of age were used for all
experiments under protocols approved by the University Animal Studies Committee.
Mice were inoculated with SeV (Fushimi strain; American Type Culture Collection [ATCC]) or UV-inactivated SeV, as previously described,
using an inoculum of 2 105 pfu, and they were monitored daily for weight
and activity. To track lung cDCs, mice were anesthetized and given 30 l of
5 mM CFSE intranasally, as previously described (2, 3, 5, 14). For blockade
of CCL28, mice were given 100 g of anti-CCL28 mAb or control IgG2b
subcutaneously every other day from PI day 3 to 19. Mucous cell metaplasia
and Muc5ac mRNA in lungs were assessed at PI day 21 as previously described (2, 3, 5).

MATERIALS AND METHODS

Lung cDC isolation. For cDC isolation, mice were killed, and intracardiac
injection of PBS was used to flush out the pulmonary and systemic circulations. BAL was performed to remove any cells in the bronchiolar or alveolar
space. Next, 1 ml of digest media was injected intratracheally. Digest medium consisted of DME supplemented with 5% fetal calf serum, penicillin/
streptokinase, 10 mM Hepes, 250 U/ml collagenase I (Worthington Biochemical), 50 U/ml DNase I (Worthington Biochemical), and 0.01% hyaluronidase (Sigma-Aldrich). The lungs were carefully dissected from the
trachea, main-stem bronchi, draining lymph nodes, and surrounding tissue.
The lungs were minced and incubated in digest media for 1 h at 37°C. During the final 15 min of incubation time, EDTA was added to a final concentration of 2 mM. After digestion, the cell mixture was passed through a
40-m pore cell strainer to generate single-cell suspensions, and erythrocytes
were removed by hypotonic lysis. Cell viability was assessed by trypan blue
exclusion. An analogous procedure was performed for removal of DCs from
spleen or draining lymph nodes, as well as for isolation of T cells from
C57BL6 or OT-II splenic tissue. Lung cDCs were identified (and other cell
populations, such as macrophages, were excluded) by flow cytometry, as
previously described (22).

Reagents and antibodies. Anti-CD16/-CD32 antibodies (clone 2.4G2;
obtained from C. Pham, Washington University, St. Louis, MO) were used
for flow cytometry, as previously described (40). Anti–mouse CCL28 mAb
or control rat IgG2b was obtained from R&D Systems. PE- or allophycocyanin-labeled antibodies against mouse CD4, CD8, CD11c, CD23, c-Kit,
FcRI (clone MAR-1), and IgE, as well as isotype control IgGs (rat and
Armenian hamster), were obtained from eBioscience or BD PharMingen.
SeV-specific CD8 T cells were monitored using tetrameric MHC/peptide
reagents for the immunodominant epitope of SeV nucleoprotein (NP324-332)
or control OVA peptide (SIINFEKL) complexed with K(b) provided by the
National Institute of Allergy and Infectious Diseases (NIAID) Tetramer
Core Facility (41). Purified anti-FcRI mAb (clone MAR-1; eBioscience)
was used for immunoprecipitation, and anti-FcRI mAb (clone JRK) obtained from J. Rivera (National Institutes of Health, Bethesda, MD) or rabbit
anti-FcRI Ab (Millipore) was used for detection of the immune complex
in Western blotting. For cross-linking experiments, functional grade Armenian hamster anti–murine FcRI or functional grade Armenian hamster
IgG isotype control antibodies were obtained from eBioscience. A secondary
goat anti–Armenian hamster IgG antibody purchased from Jackson ImmunoResearch Laboratories was also used.

Cell purification and culture. DCs were purified from lung cell suspensions using the MACS system (Miltenyi Biotec) for positive immunomagnetic selection with anti-CD11c microbeads. Using two serial purifications,
cDC purity was 95%. Cells obtained in this manner had typical cDC morphology (Fig. 4). Purified cDCs were cultured with or without cross-linking
antibodies in complete RPMI (Sigma-Aldrich) supplemented with 10% fetal
calf serum and penicillin/streptokinase (Invitrogen) for 18 h at 37°C. For T
cell proliferation experiments, cDCs were subjected to 200 cGyn before being loaded with 0.3 M of OVA peptide (OVA323-339). CD4 T cells were
purified from OT-II spleens using the Miltenyi-Biotec MACS system for
positive immunomagnetic selection. T cell purities were 95%. Irradiated
cDCs (104 per condition) were cultured for 4 d with 105 OVA-specific
CD4 T cells with or without cross-linking antibodies. For T cell proliferation, CD4 T cells were labeled with 5 M CFSE (Invitrogen) before culture, and cell proliferation was monitored by CFSE dilution, as previously
described (42). For some experiments, lung cDCs were loaded with 10 g/ml
mouse anti-OVA IgE (Serotec) for 48 h at 37°C, washed, and incubated
with or without 3 g/ml OVA protein (Sigma-Aldrich) for 18 h at 37°C,
followed by mRNA isolation from cell pellets. Mouse MC/9 mast cells were
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of asthma in the urban environment. In this setting, the increased population density, as well as other factors, may lead
to increased transmission of respiratory viral infections. If viral respiratory illnesses drive FcRI expression on lung cDCs
in humans, this process could lead to an increase in lung Th2
responses in individuals with genetic susceptibility to this
type of response. This mechanism is consistent with the increased incidence of asthma now being found for children
living in the inner city (39).
In summary, we have defined a new scheme for mucous
cell metaplasia after viral infection that depends on an IFNAR–FcRI–CCL28–IL-13 immune axis (Fig. S7, available
at http://www.jem.org/cgi/content/full/jem.20070360/DC1).
This mechanism involves cDC expression of FcRI and production of CCL28 in concert with T cell production of IL-13
and consequent mucous cell metaplasia. This immune axis may
be more active after severe infection to help explain why more
severe respiratory viral infections are associated with an increased risk of asthma. For example, the level of IgE production after SeV infection in mice appears to depend on the
severity of the infection (unpublished data). The scheme also
implies that exposure to even nonviral IgE and antigen during
the resolution of the viral response might also lead to increased
Th2 recruitment to the lung driven by additional FcRI crosslinking and CCL28 production. This mechanism would thereby
provide for an allergic-type response to nonviral antigens because Th2 cells that had migrated to the lung could be directed
against nonviral antigens. In the atopic individual, these Th2
cells could lead to the development of asthma, or an exacerbation of the disease in patients with established asthma. Each
of these mechanisms is distinct from previous proposals for
IgE–FcRI function in the traditional response to parasitic infection or allergen exposure. Thus, viral antigens and the consequent IFN-dependent antiviral response may also trigger an
“allergic” cascade, leading to disease traits that are characteristic
of asthma and other chronic airway diseases.
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obtained from the ATCC and were maintained in ATCC complete growth
medium (DME with 2 mM l-glutamine, 0.05 mM 2-ME, 4.5 g/liter glucose, and 1.5 g/liter sodium bicarbonate) supplemented with 10% fetal calf
serum and 10% Rat T-Stim (BD Biosciences) (43).

Adoptive transfer protocol. Lung cDCs were purified from C57BL6,
IFNAR/, or FceRIa/ mice and delivered intranasally to anesthetized
recipient C57BL6 or FceRIa/ mice (2.5 105 cells in 30 l of PBS given
1 d before SeV inoculation). In some experiments, cDCs were loaded with
either CFSE or TAMRA-SE (Invitrogen), as previously described (40).
No difference in transfer efficiency (engraftment) was seen with either dye
(unpublished data).
Chemotaxis assay. Chemotaxis was monitored with a modified Boyden
chamber, as previously described (46). For these experiments, CD4 T cells
were purified from naive C57BL6 spleen, and 2.5 104 cells in 50 l were
loaded in the upper chamber, which was separated from the lower chamber
by a 5-m membrane (Neuro Probe, Inc.). A 25-l aliquot of a 1:3 dilution
of supernatant from lung cDC cultures was placed in the lower chamber. In
some experiments, control rat IgG2b, rat anti–mouse CCL27 antibody, or rat
anti–mouse CCL28 antibody (100 g/ml) was added to the lower chamber.
After a 3-h incubation at 37°C, the number of cells that had transmigrated
into the lower chamber was determined by flow cytometry, as previously
described (46). Results are calculated as a migration index that represents the
ratio of cells migrating in each condition compared with the number migrating to CCL21 control (1 g/ml; R & D Systems).
Real-time PCR assay. mRNA was isolated with the RNeasy kit (Qiagen)
or Trizol (Sigma-Aldrich) and used to generate cDNA with Applied Biosystems cDNA archive kit as per the manufacturer’s instructions. Quantitative
real-time PCR assays were performed using an Applied Biosystems 7500
Fast real-time PCR system and TaqMan fast master mix. In addition to
the TaqMan rodent GAPDH control, the following TaqMan gene expression arrays (mouse primer and probe sets) for PCR were obtained from
Applied Biosystems: IL-13 (assay ID Mm00434204_m1), Muc5ac (assay ID
Mm01276725_g1), CCL28 (assay ID Mm00445039_m1), GATA-3 (assay
ID Mm00484683_m1), FcRI␣ (assay ID Mm00438867_m1), and FcRI␤
(assay ID Mm00442780_m1). For FcRI␣ and FcRI␤ mRNA levels, results
represent arbitrary units (calculated as 2[CTMaximum−CTgene]) per ng of total
RNA. For IL-13, Muc5ac, GATA-3, and CCL28 mRNA levels, results represent copy number per Gapdh copy number based on a standard curve with
the known copy number of the target and Gapdh mRNA.
Measurement of IgE and IL-13. Total IgE from mouse serum was determined by ELISA using capture and detection anti-IgE antibody pairs (BD
PharMingen) in 96-well MaxiSorp plates (Nalge Nunc). Purified mouse IgE
(BD PharMingen) was used as a control. For detection of SeV-specific IgE,
SeV-coated plates from Charles River Laboratories were substituted for capture IgE antibody-coated plates. Because no control anti-SeV IgE antibodies
are available, values represent absolute absorbance units. IL-13 levels were
determined using a commercially available ELISA kit (Invitrogen).
2768

Online supplemental material. FceRIa/ and WT mice respond similarly to SeV infection, as shown in Fig. S1. Surface marker expression on
lung cDCs from FceRIa/ and WT mice are similar, as shown in Fig. S2.
Fig. S3 shows that IFNAR expression on lung cDCs is not necessary for
FcRI expression on lung cDCs. Fig. S4 shows the effect of cDC FcRI
activation on chemotaxis of CD4 T cells. The ability of WT, but not
FceRIa/, cDC to restore postviral-induced mucous cell metaplasia in
FceRIa/ mice is demonstrated in Fig. S5. Fig. S6 shows that postviral
Muc5ac mRNA induction is inhibited with CCL28 blockade. As shown
in Fig. S7, our data support a scheme whereby an IFN–FcRI–CCL28–
IL-13 signaling pathway regulates mucous cell metaplasia after viral infection. The online version of this article is available at http://www.jem
.org/cgi/content/full/jem.20070360/DC1.
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